EP1062962A1 — Inhalation type drug dispenser
Assigned to Dott Co Ltd · Expires 2000-12-27 · 25y expired
What this patent protects
A diffusion chamber block 14 is provided in a block mounting hole 13A of an inhalant port 13, and a granular medicine diffusion chamber 17 is formed in the diffusion chamber block 14. The granular medicine diffusion chamber 17 is formed at a side of the inhalant port 13 with a gr…
USPTO Abstract
A diffusion chamber block 14 is provided in a block mounting hole 13A of an inhalant port 13, and a granular medicine diffusion chamber 17 is formed in the diffusion chamber block 14. The granular medicine diffusion chamber 17 is formed at a side of the inhalant port 13 with a granular medicine inflow opening 17A and at a side of a capsule housing hole 9 with a granular medicine outflow opening 17B. A diffusion chamber inflow passage 18 is provided to communicate an outflow air passageway 12 with the granular medicine inflow opening 17A, whereas a diffusion chamber outflow passage is provided to communicate the granular medicine outflow opening 17B with the inhalant port 13. When inhaling granular medicines in the capsule housing hole 9 via the inhalant port 13 by way of breathing action, there results in counter-flow vortex within the granular medicine diffusion chamber 17. The counter-flow cortex acts to finely break and atomize massive granular medicines, thus promoting atomization of the granular medicines.
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.